Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Harvard Business School
Moodys
Medtronic
Express Scripts

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

RAZADYNE ER Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Razadyne Er patents expire, and when can generic versions of Razadyne Er launch?

Razadyne Er is a drug marketed by Janssen Pharms and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has forty-four patent family members in thirty-five countries.

The generic ingredient in RAZADYNE ER is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.

Summary for RAZADYNE ER
International Patents:44
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 57
Clinical Trials: 18
Patent Applications: 4,546
Formulation / Manufacturing:see details
Drug Prices: Drug price information for RAZADYNE ER
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for RAZADYNE ER
DailyMed Link:RAZADYNE ER at DailyMed
Drug patent expirations by year for RAZADYNE ER
Drug Prices for RAZADYNE ER

See drug prices for RAZADYNE ER

Recent Clinical Trials for RAZADYNE ER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vanderbilt University Medical CenterPhase 1
Vanderbilt UniversityPhase 1/Phase 2
Doris Duke Charitable FoundationPhase 1/Phase 2

See all RAZADYNE ER clinical trials

Recent Litigation for RAZADYNE ER

Identify potential future generic entrants

District Court Litigation
Case NameDate
Janssen Pharmaceutica N V v. Sandoz Inc.2008-08-13
Janssen L P v. KV Pharmaceutical Company2007-12-18
ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC2007-08-09

See all RAZADYNE ER litigation

Pharmacology for RAZADYNE ER
Drug ClassCholinesterase Inhibitor
Mechanism of ActionCholinesterase Inhibitors
Synonyms for RAZADYNE ER
(-)-Galantamine
(-)-Galanthamine
(-)Galanthamine
(+/-)-Galantamine
(+/-)-Galanthamine
(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6,8,10(17),15-tetraen-14-ol
(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0;{1,12}.0;{6,17}]heptadeca-6,8,10(17),15-tetraen-14-ol
(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
(4aS,6R,8aS)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol
(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofurol[3a,3,2,-ef][2]benzazepin-6-ol
0D3Q044KCA
1008759-59-8
1354-74-1
1551-02-6
1dx6
1qti
23173-12-8
27501-22-0
357-70-0
357G700
4-27-00-02184 (Beilstein Handbook Reference)
6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aalpha,6beta,8ar*)-
6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aR,6S,8aR)-rel-
6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-
6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-
6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol,4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-
736-79-8
AB00053614_10
AB00053614-09
AC-20240
AC1L1TIM
AJ-23165
AKOS015965330
AM62710
AN-133
AN-44509
ASUTZQLVASHGKV-JDFRZJQESA-
ASUTZQLVASHGKV-JDFRZJQESA-N
BCP28966
BDBM10404
BIDD:GT0517
Bodamine
BPBio1_000480
BRD-K49481516-004-03-5
BRD-K49481516-004-04-3
BRD-K49481516-004-09-2
BRN 0093736
BSPBio_000436
BSPBio_003416
C08526
CAS-357-70-0
CCG-212961
CG0028
CHEBI:42944
CHEMBL659
CS-1217
CTK8F9985
D04292
DB00674
DivK1c_000590
DSSTox_CID_25606
DSSTox_GSID_45606
DSSTox_RID_80999
DTXSID2045606
Galantamin
Galantamin(NSC 100058)
Galantamina
Galantamina [INN-Spanish]
Galantamine
Galantamine (USAN/INN)
Galantamine [USAN:INN:BAN]
Galantamine [USAN:INN]
Galantamine, (+/-)-
Galantaminum
Galantaminum [INN-Latin]
galanthamine
Galanthamine base
Galanthamine HBr
Galanthamine, (+/-)-
Galanthamine, 12
Galanthaminum
GNT
GTPL6693
HMS2089H03
HSDB 7361
HY-76299
IDI1_000590
InChI=1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
Jilkon
KBio1_000590
KBio2_001751
KBio2_004319
KBio2_006887
KBio3_002636
KBioGR_001417
KBioSS_001751
KS-000000IN
LS-71039
Lycoremin
Lycoremine
MCULE-7156449246
MCULE-7226205054
MolPort-002-521-885
NCGC00017256-04
NCGC00017256-05
NCGC00017256-11
NCGC00024731-02
NINDS_000590
Nivalin
NSC 100058
NSC-759861
NSC759861
Pharmakon1600-01501202
Prestwick0_000588
Prestwick1_000588
Prestwick2_000588
Prestwick3_000588
Probes1_000055
Probes2_000395
Razadyne
Reminyl (TN)
SBI-0051689.P002
SCHEMBL2577
SCHEMBL3293474
SDCCGMLS-0066737.P001
SMP1_000131
SPBio_002655
Spectrum_001271
Spectrum3_001738
Spectrum4_000839
Spectrum5_001673
SR-05000001783
SR-05000001783-4
Tox21_110807
UNII-0D3Q044KCA
UNII-1T835Z585R component ASUTZQLVASHGKV-JDFRZJQESA-N
W-5162
ZINC491073
Paragraph IV (Patent) Challenges for RAZADYNE ER
Tradename Dosage Ingredient NDA Submissiondate
RAZADYNE ER CAPSULE, EXTENDED RELEASE;ORAL galantamine hydrobromide 021615 2006-03-11
RAZADYNE ER CAPSULE, EXTENDED RELEASE;ORAL galantamine hydrobromide 021615 2006-03-02

US Patents and Regulatory Information for RAZADYNE ER

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-001 Apr 1, 2005 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-002 Apr 1, 2005 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-003 Apr 1, 2005 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Expired US Patents for RAZADYNE ER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-001 Apr 1, 2005   Start Trial   Start Trial
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-003 Apr 1, 2005   Start Trial   Start Trial
Janssen Pharms RAZADYNE ER galantamine hydrobromide CAPSULE, EXTENDED RELEASE;ORAL 021615-002 Apr 1, 2005   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or Start Trial

Supplementary Protection Certificates for RAZADYNE ER

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0236684 C300140 Netherlands   Start Trial PRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Johnson and Johnson
Moodys
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
 NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

DrugPatentWatch reviews